Modeling the Budgetary Impacts of Sickle Cell Disease Gene Therapies on State Medicaid Programs

New gene therapies for sickle cell disease could increase state Medicaid budgets by an estimated $837.5 million over five years, highliging the need for novel policy interventions and payment mechanisms, such as the CMS Cell and Gene Therapy Access Model, to control costs while maintaining patient access.